Update on the management of inflammatory bowel disease: Specific role of adalimumab

Clinical and Experimental Gastroenterology

Volumn 4, Issue 1, 2011, Pages 163-172

  Guidi, Luisa ^a   Pugliese, Daniela ^a   Armuzzi, Alessandro ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Adalimumab; Anti TNF ; Crohn's disease; Ulcerative colitis

Indexed keywords

ADALIMUMAB; IMMUNOSTIMULATING AGENT; INFLIXIMAB; LAMIVUDINE; PLACEBO; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL INFECTION; ACUTE GRANULOCYTIC LEUKEMIA; ANUS FISTULA; BREAST FEEDING; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DEMYELINATING DISEASE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTERITIS; GASTROINTESTINAL INFECTION; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; LOW DRUG DOSE; LUNG INFECTION; LYMPHOMA; MAINTENANCE THERAPY; MUCOSAL ULCERATION; PEDIATRICS; PREGNANCY; PSORIASIS; PUSTULOSIS PALMOPLANTARIS; QUALITY OF LIFE; REMISSION; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; ULCER;

EID: 80955123985     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S14558     Document Type: Review

References (48)

1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627-1640.
2. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidenced-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4:28-62.
3. Lichtenstein GR, Hanauer SB, Sandborn WJ. Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-483.
4. Travis S P, Stange EF, Lemann L, et al. European evidenced-based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis. 2008;2:24-62.
5. Kornbluth A, Sachar D, et al. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-523.
6. ® Product monograph, Abbott Laboratories, Abbott Park, IL.
7. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333.
8. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239.
9. Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
10. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008; 135:1493-1499.
11. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol. 2009;104:1170-1179.
12. Sandborn WJ, Colombel J F, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohn's disease:clinical efficacy and pharmacoeconomics. Infamm Bowel Dis. 2011;17:141-151.
13. Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical beneft after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2010;31:1296-1309.
14. Lofberg R, Louis E, Reinisch W, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Infamm Bowel Dis. 2011.
15. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for Adalimumab dose intensifcation in Crohn's disease: a systematic review. Am J Gastroenterol. 2011;106:674-684.
16. Colombel J F, Schwarts DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009; 58:940-948.
17. Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior inf-liximab therapy. Aliment Pharmacol Ther. 2010;32:1228-1239.
18. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829-838.
19. Panaccione R, Sandborn WJ, D'Haens G, et al. Adalimumab maintains long-term remission in moderately to severely active Crohn's disease after infliximab failure: 1-year follow-up of GAIN trial. [abstract] Gastroenterolog y. 2008;134:A133.
20. Ma C, Panaccione R, Heitman SJ, et al. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment Pharmacol Ther. 2009;15(30):977-986.
21. Colombel JF, Rutgeerts P, Sandborn WJ. Deep remission for adalimumab-treated patients with moderate to severe ileocolonic Crohn's disease: results from EXTEND [abstract]. J Crohns Colitis. 2010;4:S10.
22. Colombel J F, Rutgeerts P, Sandborn WJ. Deep remission predicts long-term outcomes for Adalimumab-treated patients with Crohn's disease: data from EXTEND [abstract]. Gut. 2010;59(Suppl 3):A80.
23. Rosh JR, Lerer T, Markowitz J, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric crohn's disease. Am J Gastroenterol. 2009;104:3042-3049.
24. Russell RK, Wilson ML, Loganathan S, et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:946-953.
25. Hyams JS, Griffths AM, Markowitz J, et al. Induction and maintenance adalimumab therapy for the treatment of moderate to severe Crohn's disease in children [abstract]. Gastroenterology. 2011;140(Suppl 1): S90.
26. Peyrin-Biroulet L, Laclotte C, Roblin X, et al. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol. 2007; 13:2328-2332.
27. Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther. 2008;28:966-972.
28. Aff W, Leighton JA, Hanauer SB, et al. Open-label study of adali-mumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Infamm Bowel Dis. 2009;15:1302-1307.
29. Gies N, Kroeker KI, Wong K, et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther. 2010;32:522-528.
30. Taxonera C, Estellés J, Blanco I, et al. Adalimumab for ulcerative colitis patients previously treated with infliximab: outcomes at short and long term and predictors of response. Aliment Pharmacol Ther. 2011;33:340-348.
31. Hudis N, Rajca B, Polyak S, et al. The outcome of active ulcer-ative colitis treated with adalimumab [abstract]. Gastroenterology. 2009;136:A661.
32. García-Bosch O, Aceituno M, Perez J, et al. Efficacy of adalimumab in the treatment of ulcerative colitis [abstract]. J Crohns Colitis. 2010;4:S55.
33. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780-787.
34. Reinisch W, Sandborn WJ, Kumar A, et al. 52-week clinical efficacy with adalimumab in patients with moderately to severely active ulcer-ative colitis who failed corticosteroids and/or immunosoppresants [abstract]. J Crohns Colitis. 2011;5:S10.
35. Sandborn WJ, Van Assche G, Thakkar RB, et al. Adalimumab improves health-related quality of life for 52 weeks in patients with ulcerative colitis [abstract]. J Crohns Colitis. 2011;5:S87.
36. Sandborn WJ, Va n Assche GA, Reinisch W, et al. Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe ulcerative colitis [abstract]. Gastroenterology. 2011;140(5 Suppl 1):S123-S124.
37. Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Infamm Bowel Dis. 2009;15:1308-1319.
38. Shale MJ, Seow CH, Coffn S, et al. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:20-34.
39. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti- tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30-35.
40. Fiorino G, Allez M, Malesci A, et al. Review article: TNFα induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29:921-927.
41. Karmiris K, Paintaud G, Noman M, et al. Infuence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137:1628-1640.
42. Mahadevan U, Miller JK, Wolf DC. Adalimumab levels detected in cord blood and infants exposed in utero [abstract]. Gastroenterology. 2011;140(5 Suppl 1):S61-S62.
43. Johnson DL, Jones KL, Chambers CD, et al. Pregnancy outcome in women exposed to adalimumab: the OTIS autoimmune disease in pregnancy project [abstract]. Gastroenterology. 2009;136(5 Suppl 1):A27.
44. Marchioni RM, Kerner C, Lichtenstein GR. Anti-TNF therapy and fetal risk: a systematic review of the literature [abstract]. Gastroenterology. 2011;140(5 Suppl 1):S772.
45. Ben-Horin S, Yavzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol. 2010;8:475-476.
46. D'Haens G, Baert F, Van Assche G, et al. Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667.
47. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362:1383-1395.
48. van der Valk ME, van Oijen MG, Siersema PD, et al. Crohn's disease patients treated with adalimumab beneft from co-treatment with immunomodulators: results from a nationwide study in the Netherlands [abstract]. Gastroenterology. 2011;140(5 Suppl 1):S264.